Verici Dx PLC Launch of patient-focused educational tool

RNS Number : 6504Q

Verici Dx PLC

31 May 2024

 

Non-regulatory announcement

Verici Dx plc

("Verici Dx" or the "Company") 

 

Verici Dx Launches an interactive patient-focused educational tool, the Patient Journey

Providing a detailed overview of all stages of the kidney transplant journey

 

Verici Dx (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, is pleased to announce the introduction of its patient-focused education resource, for use by patients, care givers and transplant teams in the form of a new dedicated website showing the kidney transplant patient journey (https://patientjourney.vericidx.com). This online tool is designed to illustrate a generalised pathway for patients as they consider their kidney healthcare and offer a platform for patients to share their own experiences digitally including video clips. It also includes video clips from transplant team members to share their thoughts on what to expect. This enhancement is part of Verici Dx's ongoing commitment to supporting patients with comprehensive and accessible information.

 

At Verici Dx, we are committed to improving patient outcomes and believe that access to reliable, detailed information is a cornerstone of effective healthcare. This new tool provides a detailed overview of all stages of the kidney transplant journey-from the initial diagnosis and treatment of kidney disease, through early-stage monitoring and on to long-term care after a kidney transplant. This resource is designed to empower patients and caregivers with knowledge and understanding, helping them navigate the complexities of kidney disease and transplantation with confidence.

 

The new section of the website is intended to offer a valuable tool for those seeking guidance at each step of their journey and we look forward to demonstrating this to patients at the Transplant Games, which will take place in Birmingham Alabama, from 5 - 10 July 2024. We invite everyone interested in learning more about the kidney transplant process to join us there or visit our updated website at https://patientjourney.vericidx.com.

 

Commenting on the update, Andrew Silverman, Director of Scientific Communications, said:

 

"We are excited to launch this new section of the website as it directly aligns with our mission to enhance patient care and support. It ensures that patients and caregivers have access to the latest information and best practices for kidney transplant care, and we are confident that it will improve communication between all parties involved in the journey."

 

Enquiries:

 

Verici Dx	www.vericidx.com
Sara Barrington, CEO	[e-mail]
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser & Broker)	Tel: [phone]
Aubrey Powell / Sam Butcher

 

 

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRAVFLBXZELEBBD